INTRODUCTION
While thrombocytopenia is present in <1% of newborn infants, 1 it may be found in as many as 22 to 35% of Neonatal ICU admissions. 2, 3 Of these, 5 to 7% are classified as 'severe' (<50,000/mm 3 ) 3 and can be attributed to increased platelet destruction and/or decreased production. 4 The former mechanism occurs more frequently and includes both immune-mediated and nonimmune-mediated disorders, predominantly infection, with or without disseminated intravascular coagulation. Disorders of underproduction include primarily bone marrow replacement or aplasia syndromes. When accompanied by splenomegaly, etiologic consideration must be given to infiltrative metabolic disorders such as the mucolipidoses and mucopolysaccharidoses in addition to infectious and neoplastic diseases, all of which may contribute to thrombocytopenia through hypersplenism. 4 We present here a case of an infant with severe thrombocytopenia, splenomegaly and direct hyperbilirubinemia at birth diagnosed with Gaucher disease.
CASE REPORT
The male patient was delivered by cesarian section at 40 weeks gestation after 13 hours of ruptured membranes to a 25-year-old primigravida. Apgar scores were 9 and 9 at 1 and 5 minutes, respectively. Prenatal maternal labs included nonreactive rapid plasma reagin, negative Hepatitis B surface antigen, negative vaginal culture for Group B streptococcus and presence of Rubella antibodies. The mother, whose blood type is A-negative, received Rhogam after delivery. Both parents are of Albanian Muslim descent and denied consanguinity. The infant was admitted to the NICU at 2 hours of life because of tachypnea. His birth weight (3125 g), length (48.5 cm), and head circumference (32 cm) were all appropriate for gestational age. Breath sounds were clear and there was no murmur. The liver edge was palpated 4 cm below the right costal margin and the spleen tip was 1 cm below the umbilicus. Neurologic exam was normal. He was treated with oxygen, first by oxyhood and then by nasal cannula, until 2 weeks of age. Initial chest X-ray showed no acute pulmonary disease and heart size was normal. Initial CBC showed WBC 20,500/mm 3 with a normal differential, hematocrit 42.8% and platelets 13,000/mm 3 . Multiple platelets transfusions were given with eventual stabilization at 45,000 to 50,000/mm 3 . PT was 13.4 seconds, aPTT 26.6 seconds and fibrinogen 185 mg/dl (1.85 g/l), all within normal limits for age.
Platelet antigen typing revealed HPA-3a paternal platelets and HPA-3b maternal platelets, but no maternal anti-platelet antibodies were detected. Prior to the availability of the latter results, the baby was treated with 5-day courses of IVIG (400 mg/kg/day) and intravenous methylprednisolone for possible alloimmune thrombocytopenia without clinical response. Bone marrow biopsy and aspiration demonstrated adequate megakaryocytes, normal myeloid and eythroid cells and absence of leukemic or storage cells. CAT scan of the brain at 2 days of age showed a right frontal parietal hemorrhage, which resolved by 2 weeks of age. Liver function tests were abnormal with bilirubin total/direct 7.7/3.6 mg/dl (132/62 mmol/l) at birth and peaking at 9.7/5.4 mg/dl (166/92 mmol/l) and peak enzyme levels of AST 515 U/l, ALT 206 U/l, GGTP 193 U/l. While abdominal ultrasound revealed diffusely enlarged liver and spleen, normal gallbladder and bile ducts, HIDA scan revealed delayed excretion consistent with cholestasis. Abdominal flow Doppler examination demonstrated patency of hepatic, splenic and portal veins and inferior vena cava. The baby was initially treated with ampicillin and gentamicin until blood culture was negative. TORCH titers, Urine CMV antigen, and blood CMV-PCR were all negative, as were nasal and rectal cultures for enteroviruses. X-rays of the long bones were normal. Ophthalmologic evaluation was negative for choreoretinitis or cherry red spot. Additional metabolic work-up revealed normal alpha-1-antitrypsin level and phenotype (Pi-MM), galactose-1-phosphate uridyl transferase level, urine organic acids and plasma amino-acid profile. Urine was negative for reducing substances, mucopolysaccharides and oligosaccharides. Leukocyte sphinogomyelinase was 7.64 (Normal: 1.00 to 5.00) nmol/mg 
DISCUSSION
Gaucher disease is one of many lysosomal storage diseases (LSD) characterized by mutations in one of a series of enzymes involved in the degradation of glycosphingolipids resulting in intracellular accumulation of the immediate upstream substrate especially in mononuclear phagocytes, which function abnormally or die. 5 The distribution of the cells affected in this manner determines the clinical manifestations of the particular LSD. Patients with unexplained hepatosplenomegaly, anemia, thrombocytopenia, neurologic degeneration, cardiomyopathy, renal dysfunction and/or cutaneous abnormalities must be evaluated for LSD. 5 Like many of the other LSD, patients with Gaucher disease do not have dysmorphic features. In the patient described here, metabolic evaluation was undertaken when the thrombocytopenia persisted despite treatment with numerous transfusions, steroids and IVIG and neither viral nor bacterial infection could be documented (see Figure 1) . Gaucher disease is characterized by autosomal recessive mutations at both of the chromosomal 1q21 loci resulting in deficient activity of the enzyme b-glucocerebrosidase. Accumulation of glucocerebroside results in one of three phenotypes: (1) type 1 or non-neuronopathic (2) type 2, acute neuronopathic and (3) type 3, subacute neuronopathic. While type 1 disease shows a predilection for individuals of Ashkenazi Jewish descent, the much more rare types 2 and 3 present in all ethnic groups. 6 While patients with type 1 disease present at a later age, have relatively mild symptoms and have a good prognosis for long-term survival, the opposite is true in all respects for patients with type 2 disease. Patients with type 3 are intermediate in disease severity and prognosis relative to types 1 and 2. 7 The gene for the 497 amino-acid glycoprotein enzyme consists of 11 exons and 10 introns, within which greater than 100 mutations have been described. 6 However, four 'public' mutations F N370S, L444P, 84GG and IVS2 ( þ 1) F account for >90% of type 1 mutant alleles. 6 While the N370S and L444P mutations have been frequently associated with mild and severe phenotypes, respectively, genotype-phenotype correlations in many instances are inconsistent at best. 7 Prior studies have revealed wide phenotypic differences within genotypic groups and even between siblings suggesting that combinations of other modifying genetic and nongenetic factors are operative. 8 The D409 H mutation described in this case report is the second most common mutation described in Greek patients with Gaucher disease. 9 Homozygotes have been described with cardiovascular valvular disease 10 as well as early-onset neuronopathic disease. 9 When present as a single copy, greater phenotypic heterogeneity has been described. 8, 11 In the current report, visceromegaly and thrombocytopenia were the predominant features. Although there was no evidence of either cardiac or neurological disease, given the early age of presentation, these and other manifestations may still develop. The long-term clinical picture is critical in light of data demonstrating the efficacy of enzyme replacement therapy in ameliorating the organomegaly, hematological abnormalities and bone disease associated with Gaucher disease, but not the central nervous system involvement. 6 Thus, in patients with severe neuronopathic variants of this disorder, therapy is generally not undertaken. 6 We speculate that heightened awareness of the association of lysosomal storage diseases with visceromegaly and unremitting hematological abnormalities may lead to diagnosis and treatment prior to expression of the full clinical phenotype in individual patients.
